Skip to main content
Caplight Logo









Lumen Bio

Lumen Bio

Private
Seattle, WashingtonHealthcare & Life Scienceshttps://www.lumen.bio/

Last Round

Series C

Extension

Oct 8, 2025

Total Funding Raised

$56M

Company Overview

Lumen Bioscience is a biotechnology company that develops orally delivered biologic drugs for highly prevalent diseases using a proprietary spirulina-based biomanufacturing platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Clean Manufacturing

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Application

Keywords

biotechnologyoral biologicsspirulina platformbiomanufacturingdrug discoveryoral deliverytherapeutic proteinscGMP manufacturingsynthetic biologyprotein engineeringbiologics manufacturingalgae-based drugsbio-pharmastrain engineeringlow-cost biologics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Lumen Bio Comparables

Compare Lumen Bio with similar companies based on industry and business-model similarity.

Lumen Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Vedanta Biosciences
73%
Seres Therapeutics Inc
65%
Rani Therapeutics
62%

Lumen Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series C ExtensionOct 8, 2025
GrantJan 4, 2023
GrantJan 4, 2023
GrantJan 27, 2021
GrantSep 24, 2020
Series A
Dec 5, 2017

Key People

Founding team and executive leadership

David Boone

CTO and Founder

Founding Team

Lumen Bio Investors

Notable investors and investment history

Lumen Bio investors
InvestorRounds
CARB-XGrant
Gates FoundationGrant, Series C Extension
Bioeconomy CapitalSeries A, Grant
WestRiver GroupGrant, Series C Extension
Columbia Pacific AdvisorsGrant
Medical Technology Enterprise ConsortiumGrant
Department of EnergyGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 28, 2025

    Monthly visitors grew 204% MoM.

  • Oct 27, 2024

    Monthly visitors grew 160% MoM, reaching 710.

Lumen Bio Filings

Explore SEC and related filing metadata, where available.

Lumen Bio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Lumen Bio's valuation, stock price, and market status.

Is Lumen Bio a public or private company?

Lumen Bio is a private company.

What is the current stock price of Lumen Bio?

Lumen Bio is a private company with no public stock price. No recent secondary market data is available.

How much is Lumen Bio worth (valuation)?

Valuation information for Lumen Bio is not publicly available.

Can I buy Lumen Bio stock?

Lumen Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Lumen Bio's last funding round?

Lumen Bio's most recent funding round was Series B on September 1, 2020.

Who are the main investors in Lumen Bio?

Investor information for Lumen Bio is not publicly disclosed.

Will Lumen Bio IPO soon?

No public IPO plans have been announced for Lumen Bio.

How can I track Lumen Bio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Lumen Bio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSeattle, Washington
Employee Range1
Year Founded2017
Last FundingOct 8, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?